What Is The Current and Historic Market Size Analysis Of The Pulmonary Drug Delivery Devices Market?
The pulmonary drug delivery devices market has seen considerable growth due to a variety of factors.
• The pulmonary drug delivery devices market has grown robustly in recent years. It is projected to increase from $49.52 billion in 2024 to $53.21 billion in 2025, with a compound annual growth rate (CAGR) of 7.4%.
The historical growth is attributed to the rising incidence of respiratory conditions like chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis, the growing elderly population, heightened awareness about respiratory health, increased healthcare spending in emerging markets, and the growing use of homecare for respiratory therapy.
What Is The Forecast For The Pulmonary Drug Delivery Devices Market Size?
The pulmonary drug delivery devices market is expected to maintain its strong growth trajectory in upcoming years.
• The pulmonary drug delivery devices market is anticipated to reach $69.91 billion by 2029, growing at a CAGR of 7.1%.
Factors like demand for personalized medicine in respiratory care, home healthcare expansion, and increased R&D investment drive growth. Trends include telehealth integration, wearables for self-management, and 3D printing in manufacturing.
What Are The Essential Drivers Behind The Growth Of The Pulmonary Drug Delivery Devices Market?
The rise in respiratory conditions is likely to fuel the expansion of the pulmonary drug delivery devices market. Respiratory conditions are diseases or ailments affecting the lungs and airways, thus influencing human breathing patterns. This spike in respiratory conditions is attributed to several factors such as increased air pollution levels, growth in smoking rates, urban development, climate change, and an aging population. Pulmonary drug delivery devices are crucial in treating respiratory conditions as they facilitate the direct administration of medication to the lungs. For example, the Centers for Disease Control and Prevention (CDC), a US-based national public health agency, reported in May 2024 that the current prevalence of asthma among adults aged 18 and over increased from 8.0% in 2021 to 8.7% in 2022. Consequently, this surging prevalence of respiratory conditions is anticipated to drive the expansion of the pulmonary drug delivery devices market.
How Is The Global Pulmonary Drug Delivery Devices Market Divided Into Key Segments?
The pulmonary drug delivery devices market covered in this report is segmented –
1) By Product Type: Dry Powder Inhalers, Metered Dose Inhalers, Nebulizers
2) By Application: Asthma, Cystic Fibrosis, Chronic Obstructive Pulmonary Disease, Other Applications
3) By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, E-Commerce
Subsegments:
1) By Dry Powder Inhalers (DPIs): Single-Dose DPIs, Multi-Dose DPIs
2) By Metered Dose Inhalers (MDIs): CFC-Based MDIs, HFA-Based MDIs
3) By Nebulizers: Jet Nebulizers, Ultrasonic Nebulizers, Mesh Nebulizers
Pre-Book The Pulmonary Drug Delivery Devices Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What New Trends Are Influencing The Pulmonary Drug Delivery Devices Market?
Pioneering businesses in the market for pulmonary drug delivery devices are coming up with creative solutions like small-volume nebulizers with enhanced features, to meet customer needs more effectively. A small-volume nebulizer (SVN) is a healthcare device intended for the provision of medication in mist form to individuals dealing with respiratory ailments like asthma, chronic obstructive pulmonary disease (COPD), or cystic fibrosis. For example, Medline Industries LP, a healthcare enterprise from the US, introduced the Hudson RCI TurboMist small-volume nebulizer in May 2024. This transformative invention is developed to quickly deliver medical treatments in just about three minutes. This modern nebulizer can administer medication 2.5 times faster compared to regular nebulizers, cutting therapy durations by approximately 70%. This upgraded drug delivery substantially minimizes therapy periods, which in turn aids health providers by maximizing patient turnover and enriches the patient journey by reducing therapy session lengths.
Who Are the Key Players In The Pulmonary Drug Delivery Devices Market?
Major companies operating in the pulmonary drug delivery devices market are:
• Medtronic plc
• Air Liquide S.A.
• Becton Dickinson and Company
• Koninklijke Philips N.V.
• Medline Industries Inc.
• ResMed Inc.
• Drägerwerk AG And Co. KGaA
• Smiths Group plc
• AptarGroup Inc.
• Chiesi Farmaceutici S.p.A.
• Teleflex Incorporated
• Masimo Corporation
• Fisher And Paykel Healthcare Limited
• Invacare Corporation
• Vyaire Medical Inc.
• Inogen Inc.
• Drive DeVilbiss Healthcare Inc.
• Hovione
• Hamilton Medical AG
• GaleMed Corporation
• Allied Healthcare Products Inc.
• Precision Medical Inc.
• Salter Labs Inc.
• Nidek Medical Products Inc.
What Are The Regional Insights Into The Pulmonary Drug Delivery Devices Market?
North America was the largest region in the pulmonary drug delivery devices market in 2023. The regions covered in the pulmonary drug delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
